Description: Our goal in this article is to dive deeper into the role longevity swaps could play in the US PRT market by drawing comparisons to the UK and highlighting recent commercial developments that can jump start the US market’s need for longevity reinsurance.

Description: Reinsurance can be used as a tool to improve profitability and competitiveness on in force and new business for companies. Emerging reinsurance solutions will help organizations better manage their capital in different ways. During this webcast, the following solutions will be covered: Use of reinsurance to manage and improve capital and profitability Turning spread-based business into fee-based business Strategic use of affiliate and sidecar reinsurance

Description: In this session 116 PD of the New York Annual Meeting the panel discusses factors which led to the development of alternative risk transfer transactions in the property and casualty markets, and review techniques used to transfer and trade insurance risks within the capital markets. From the Record of the Society of Actuaries, Vol. 24, No. 3.

Description: Given all the noise surrounding the topic of avian influenza today, how can actuaries distill the mass of information—which is often conflicting—into the critical questions to raise and explore within their own organizations?

Description: Panel discusses securitization as a popular method for improving returns and clearing up balance sheets. From the Record of the Society of Actuaries, Vol. 23, No. 3., Session 74 PD of the Washington Annual Meeting

Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.